Nyxoah (NYXH)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $91.61M
Last updated: Nov 17, 2026 at 4:10 PM ET
Nyxoah (NYXH) Statistics
Nyxoah (NYXH) has a market cap of $91.61M. Its share count is up 169.50% from a year earlier. Revenue grew 429.37% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $91.61M |
|---|---|
| Latest price (Nov 17, 2026) | $0.90 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.6x and 1.2x. Its year-end P/S ranged from 15.3x to 557.0x from 2021 to 2025.
| P/S Ratio | 2.6x |
|---|---|
| P/B Ratio | 1.2x |
| P/TBV Ratio | 1.2x |
Price Statistics
The stock is down 82.00% over 52 weeks and trades 23.08% below its 50-day average.
| Beta (1Y) | 2.45 |
|---|---|
| 52-Week Change | -82.00% |
| 1-Month Change | -5.68% |
| 3-Month Change | -45.46% |
| 6-Month Change | -67.98% |
| 5-Year Change | -96.53% |
| Total Return (1Y) | -82.00% |
| Total Return (3Y CAGR) | -43.61% |
| Total Return (5Y CAGR) | -47.59% |
| Max Drawdown (1Y) | -84.49% |
| Max Drawdown (3Y) | -95.84% |
| Sharpe Ratio (1Y) | -1.72 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $1.17 |
| 200-Day Average | $2.26 |
| 52-Week Range | $0.80 to $5.39 |
| RSI (14 Days) | 38.5 |
| Average Volume (20 Days) | 237.84K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.19x current liabilities, and total debt is 0.67x shareholder equity.
| Current Ratio | 2.19x |
|---|---|
| Quick Ratio | 2.08x |
| Debt / Equity | 0.67x |
| Interest Coverage | -3.57x |
Returns and Efficiency
Return on invested capital is -65.86% over the last 12 months, against a 5-year average of -39.40%.
| Return on Equity (ROE) | -138.65% |
|---|---|
| Return on Assets (ROA) | -63.36% |
| Return on Invested Capital (ROIC) | -65.86% |
| Return on Capital Employed (ROCE) | -69.52% |
| ROE (5Y Average) | -64.87% |
| ROA (5Y Average) | -37.16% |
| ROIC (5Y Average) | -39.40% |
| Asset Turnover | 0.25x |
| Inventory Turnover | 3.25x |
| Receivables Turnover | 3.30x |
| Cash Conversion Cycle | -21 days |
Scores
NYXH has an Altman Z-Score of -3.94, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.94 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was EUR 29.85M over the last 12 months.
| Revenue | EUR 29.85M |
|---|---|
| Revenue Growth (YoY) | +429.37% |
| Gross Profit | EUR 16.21M |
| Operating Income | EUR -84.45M |
| Pretax Income | EUR -90.60M |
| Net Income | EUR -92.73M |
| EBITDA | EUR -68.25M |
| EBIT | EUR -73.60M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 45.70% of the EUR 148.72M in total assets.
| Working Capital | EUR 51.21M |
|---|---|
| Shareholder Equity | EUR 67.96M |
| Tangible Book Value | EUR 67.61M |
| Total Assets | EUR 148.72M |
| Total Liabilities | EUR 80.77M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After EUR 2.47M of capital spending, operating cash flow left EUR -74.80M of free cash flow.
| Operating Cash Flow | EUR -72.33M |
|---|---|
| Capital Expenditures | EUR 2.47M |
| Free Cash Flow | EUR -74.80M |
| Depreciation and Amortization | EUR 6.64M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -282.89%.
| Gross Margin | 54.32% |
|---|---|
| Operating Margin | -282.89% |
| Pretax Margin | -303.50% |
| Net Margin | -310.64% |
| EBITDA Margin | -228.62% |
| EBIT Margin | -246.55% |
| FCF Margin | -250.58% |
| Gross Margin (5Y Average) | 63.57% |
Growth
Revenue grew 48.11% a year over 3 years.
| Revenue Growth (3Y CAGR) | +48.11% |
|---|---|
| Revenue Growth (5Y CAGR) | +170.65% |
Peer Position
Against 12 similar companies, NYXH has the 4th highest P/S.
P/S RatioPeer median 1.1x
ROICPeer median -28.34%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.76%
| P/S Ratio | 2.6x vs 1.1x median |
|---|---|
| ROIC | -65.86% vs -28.34% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +429.37% vs +13.76% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NYXH
What is NYXH's market cap?
Nyxoah has a market cap of $91.61M.
How many shares of NYXH are outstanding?
Nyxoah has 100.87M shares outstanding. The count is up 169.50% from a year earlier.
Does NYXH pay a dividend?
No. Nyxoah does not pay a dividend.
NYXH pages: Overview, Charting, Financials, Statistics, Valuation, Competitors